{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:06Z","timestamp":1792448646821,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":291,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007105\u201345"],"award-info":[{"award-number":["T32GM007105\u201345"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005562","name":"NC Biotechnology Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["I-1829"],"award-info":[{"award-number":["I-1829"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1074\/jbc.ra119.011857","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T02:45:10Z","timestamp":1577760310000},"page":"1565-1574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A highly selective inhibitor of interleukin-1 receptor\u2013associated kinases 1\/4 (IRAK-1\/4) delineates the distinct signaling roles of IRAK-1\/4 and the TAK1 kinase"],"prefix":"10.1016","volume":"295","author":[{"given":"Scott A.","family":"Scarneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2217-455X","authenticated-orcid":false,"given":"Philip F.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly W.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Gurbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-5923","authenticated-orcid":false,"given":"Kenneth D.","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.J.","family":"Haystead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.RA119.011857_bib1","first-page":"179","article-title":"TNF\u03b1 as a therapeutic target in rheumatoid arthritis","volume":"43","author":"Feldmann","year":"1994","journal-title":"Circ. Shock"},{"key":"10.1074\/jbc.RA119.011857_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1074\/jbc.RA119.011857_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cytogfr.2007.04.002","article-title":"How TNF was recognized as a key mechanism of disease","volume":"18","author":"Clark","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1074\/jbc.RA119.011857_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis"},{"key":"10.1074\/jbc.RA119.011857_bib5","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol"},{"key":"10.1074\/jbc.RA119.011857_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat. Rev. Immunol"},{"key":"10.1074\/jbc.RA119.011857_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res. Ther"},{"key":"10.1074\/jbc.RA119.011857_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1358\/dot.2016.52.8.2543995","article-title":"JAK inhibitors: A broadening approach in rheumatoid arthritis","volume":"52","author":"Lam","year":"2016","journal-title":"Drugs Today (Barc.)"},{"key":"10.1074\/jbc.RA119.011857_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2010.02.013","article-title":"Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals","volume":"135","author":"Henderson","year":"2010","journal-title":"Clin. Immunol"},{"key":"10.1074\/jbc.RA119.011857_bib10","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.24552","article-title":"The critical role of kinase activity of interleukin-1 receptor\u2013associated kinase 4 in animal models of joint inflammation","volume":"60","author":"Koziczak-Holbro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1074\/jbc.RA119.011857_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4049\/jimmunol.1203103","article-title":"MyD88: a critical adaptor protein in innate immunity signal transduction","volume":"190","author":"Warner","year":"2013","journal-title":"J. Immunol"},{"key":"10.1074\/jbc.RA119.011857_bib12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4049\/jimmunol.0802361","article-title":"IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease","volume":"183","author":"Staschke","year":"2009","journal-title":"J. Immunol"},{"key":"10.1074\/jbc.RA119.011857_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1189\/jlb.1103543","article-title":"Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system","volume":"75","author":"Netea","year":"2004","journal-title":"J. Leukoc. Biol"},{"key":"10.1074\/jbc.RA119.011857_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00011-009-0088-5","article-title":"IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation","volume":"59","author":"Silver","year":"2010","journal-title":"Inflamm. Res"},{"key":"10.1074\/jbc.RA119.011857_bib15","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.bmcl.2008.04.039","article-title":"IRAK-4 inhibitors: II. A structure-based assessment of imidazo[1,2-a]pyridine binding","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg Med. Chem. Lett"},{"key":"10.1074\/jbc.RA119.011857_bib16","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.bmcl.2008.04.058","article-title":"IRAK-4 inhibitors: Part 1. A series of amides","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg Med. Chem. Lett"},{"key":"10.1074\/jbc.RA119.011857_bib17","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1016\/j.bmcl.2008.04.042","article-title":"IRAK-4 inhibitors: Part III. A series of imidazo[1,2-a]pyridines","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1074\/jbc.RA119.011857_bib18","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1016\/j.bmcl.2015.10.060","article-title":"Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4","volume":"25","author":"Wang","year":"2015","journal-title":"Bioorg Med. Chem. Lett"},{"key":"10.1074\/jbc.RA119.011857_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.chembiol.2017.07.011","article-title":"Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-\u03b1 inhibition for cancer and autoimmune disease","volume":"24","author":"Totzke","year":"2017","journal-title":"Cell Chem. Biol"},{"key":"10.1074\/jbc.RA119.011857_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/jm5016044","article-title":"Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor\u2013 associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders","volume":"58","author":"Chaudhary","year":"2015","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.RA119.011857_bib21","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.bmcl.2006.03.020","article-title":"Discovery and initial SAR of inhibitors of interleukin-1 receptor\u2013associated kinase-4","volume":"16","author":"Powers","year":"2006","journal-title":"Bioorg Med. Chem. Lett"},{"key":"10.1074\/jbc.RA119.011857_bib22","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.str.2006.11.001","article-title":"Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine\/threonine kinase with tyrosine as a gatekeeper","volume":"14","author":"Wang","year":"2006","journal-title":"Structure"},{"key":"10.1074\/jbc.RA119.011857_bib23","doi-asserted-by":"crossref","first-page":"17058","DOI":"10.1038\/s41598-018-35189-7","article-title":"Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion","volume":"8","author":"Scarneo","year":"2018","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.RA119.011857_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13075-019-2073-x","article-title":"Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice","volume":"21","author":"Scarneo","year":"2019","journal-title":"Arthritis Res. Ther"},{"key":"10.1074\/jbc.RA119.011857_bib25","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1126\/science.1081902","article-title":"Pyogenic bacterial infections in humans with IRAK-4 deficiency","volume":"299","author":"Picard","year":"2003","journal-title":"Science"},{"key":"10.1074\/jbc.RA119.011857_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.immuni.2008.09.015","article-title":"IRAK-4\u2013 and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans","volume":"29","author":"Isnardi","year":"2008","journal-title":"Immunity"},{"key":"10.1074\/jbc.RA119.011857_bib27","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.4049\/jimmunol.179.7.4754","article-title":"TLR9 activation induces normal neutrophil responses in a child with IRAK-4 deficiency: involvement of the direct PI3K pathway","volume":"179","author":"Hoarau","year":"2007","journal-title":"J. Immunol"},{"key":"10.1074\/jbc.RA119.011857_bib28","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1021\/acs.jmedchem.7b00231","volume":"60","author":"Lee","year":"2017","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.RA119.011857_bib29","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.3390\/molecules23123136","article-title":"Design of a novel and selective IRAK4 inhibitor using topological water network analysis and molecular modeling approaches","volume":"23","author":"Lee","year":"2018","journal-title":"Molecules"},{"key":"10.1074\/jbc.RA119.011857_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/jm500480k","article-title":"Discovery of type II inhibitors of TGF\u03b2-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)","volume":"58","author":"Tan","year":"2015","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.RA119.011857_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem"},{"key":"10.1074\/jbc.RA119.011857_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nprot.2006.149","article-title":"Assay of protein kinases using radiolabeled ATP: a protocol","volume":"1","author":"Hastie","year":"2006","journal-title":"Nat. Protoc"},{"key":"10.1074\/jbc.RA119.011857_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817498565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817498565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.RA119.011857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T21:34:07Z","timestamp":1654292047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925817498565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0021925817498565"],"URL":"https:\/\/doi.org\/10.1074\/jbc.ra119.011857","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A highly selective inhibitor of interleukin-1 receptor\u2013associated kinases 1\/4 (IRAK-1\/4) delineates the distinct signaling roles of IRAK-1\/4 and the TAK1 kinase","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.RA119.011857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}